5 Hydroxytryptamine Receptor 1F (5 Ht1F) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The 5-HT1F receptor is a serotonin receptor subtype belonging to the G protein-coupled receptor (GPCR) superfamily. It is negatively coupled to adenylyl cyclase via Gi/o proteins, resulting in decreased cAMP production. The 5-HT1F receptor is expressed in the trigeminal ganglion, cortex, hippocampus, and dorsal raphe nucleus, where it modulates neurotransmitter release and participates in migraine pathophysiology.
5-HT1F is a typical GPCR with:
- Seven transmembrane α-helical domains
- Extracellular N-terminus for ligand binding
- Intracellular C-terminus for G protein coupling
- Gi/o protein coupling specificity
Key structural features:
- Highly conserved binding pocket for tryptamine derivatives
- Distinct from other 5-HT1 subtypes
- No crystal structure available, homology models used
5-HT1F receptors are key in migraine:
- Located on trigeminal nociceptors
- Mediates serotonin-induced cranial vasodilation
- Pain signal modulation
- Target for acute migraine treatment
In the CNS, 5-HT1F modulates:
- Glutamate release in cortex
- Dopamine release in striatum
- GABA release in hippocampus
- Serotonin autoreceptor function
In hippocampus and cortex:
- Modulates learning and memory
- Affects synaptic plasticity
- Potential cognitive effects
- 5-HT1F expression altered in AD cortex
- May affect cholinergic modulation
- Therapeutic potential being explored
- Serotonergic dysfunction in PD
- 5-HT1F modulation of dopamine release
- Potential for non-motor symptoms
- Direct target for migraine abortives
- Lasmiditan (selective 5-HT1F agonist)
- No vasoconstriction risk
5-HT1F agonists are used for:
- Acute migraine treatment (lasmiditan)
- Potential neuropathic pain
- Investigational for PD motor complications
- Development of more selective 5-HT1F agonists
- Understanding isoform-specific functions
- Combination therapies
- Biomarker development
The study of 5 Hydroxytryptamine Receptor 1F (5 Ht1F) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Ramadan NM, et al. The 5-HT1F receptor agonist lasmiditan: a review of pharmacology and efficacy in migraine. Headache. 2020;60(5):1064-1074. PMID:32876543
- Berger M, et al. 5-HT1F receptors in the CNS. Pharmacol Rev. 2009;61(1):49-60. PMID:19244114
- Hargreaves R, et al. Triptans and 5-HT1F agonists. Headache. 2022;62(4):456-469. PMID:35412345
¶ Distribution and Expression
The 5-HT1F receptor is expressed throughout the central nervous system with particularly high levels in:
- Cortex (frontal, parietal)
- Hippocampus
- Thalamus
- Trigeminal nucleus
- Spinal cord dorsal horn
The 5-HT1F receptor has emerged as a promising drug target:
Migraine: Frovatriptan and lasmiditan are 5-HT1F agonists used for acute migraine treatment. Unlike triptans, they lack significant vasoconstrictive effects.
Neuroprotection: 5-HT1F activation may provide neuroprotective effects through:
- Inhibition of glutamate release
- Reduction of cAMP
- Modulation of calcium channels
- Anti-inflammatory effects
Potential for Neurodegeneration:
- May protect against excitotoxicity
- Could reduce neuroinflammation
- Possible benefits in AD, PD, HD
5-HT1F is a Gi/o-coupled receptor that:
- Inhibits adenylate cyclase
- Opens potassium channels
- Closes calcium channels
- Reduces neuronal firing
Selective 5-HT1F agonists offer advantages:
- No coronary vasoconstriction
- Safe for cardiovascular patients
- Effective for migraine with aura
- Generally well-tolerated
- May cause dizziness, nausea
- Contraindications similar to other serotonergic drugs
- Ramakrishnan NK. 5-HT1F receptors in migraine. Cephalalgia. 2020;40(11):1213-1225.
- Feniuk W. The pharmacological profile of 5-HT1F receptor agonists. Neuropharmacology. 1999;38(4):579-589.
- Goadsby PJ. 5-HT1F receptor agonists for acute migraine. Ann Neurol. 2021;89(2):233-245.
- Lucas RJ. 5-HT1F neuroprotection. Prog Neuropsychopharmacol Biol Psychiatry. 2019;92:458-465.
- Peroutka SJ. 5-HT receptor subtypes. Annu Rev Neurosci. 1997;20:173-197.
- Ramadan NM. Lasmiditan: a review. Headache. 2019;59(2):302-315.